<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733954</url>
  </required_header>
  <id_info>
    <org_study_id>US10012</org_study_id>
    <nct_id>NCT00733954</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis</brief_title>
  <official_title>A Comparison Between Clobetasol Propionate (ClobexÂ®) Spray and Clobetasol Propionate Ointment With Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate
      Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in
      Moderate to Severe Stable Plaque Psoriasis. Subjects will be enrolled and randomized into one
      of two groups: clobetasol propionate Spray for 4 weeks of treatment or clobetasol propionate
      ointment for 2 weeks of treatment with a 2 week follow-up visit for each group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale</measure>
    <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
    <description>Success Rate on Overall Disease Severity (ODS) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe with Clear/Almost Clear being best and Severe/Very Severe being worst) from Baseline to End of Treatment (wk 4 - clobetasol propionate spray; wk 2 - clobetasol propionate ointment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to After Two Weeks of Treatment Based on the Overall Disease Severity (ODS) Scale</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Success Rate on Overall Disease Severity (ODS) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being best and Severe/Very Severe being worst from Baseline to after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to 2 Weeks Post Treatment Based on the Overall Disease Severity (ODS) Scale</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Success Rate on Overall Disease Severity scale (Clear/Almost Clear, Moderate, Severe/Very Severe) with Clear/Almost Clear being best and Severe/Very Severe being worst at 2 weeks post treatment (week 6 - clobetasol propionate spray and week 4 - clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to After Two Weeks of Treatment</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Success Rate of decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to After Two Weeks of Treatment</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Success Rate of decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to After Two Weeks of Treatment</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Success Rate of decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to End of Treatment</measure>
    <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
    <description>Success Rate on decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to End of Treatment</measure>
    <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
    <description>Success Rate on decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to End of Treatment</measure>
    <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
    <description>Success Rate on decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to Two Weeks Post Treatment</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Success Rate on decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to Two Weeks Post Treatment</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Success Rate on decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to Two Weeks Post Treatment</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Success Rate on decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline and 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to After Two Weeks of Treatment</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Percent decrease in Body Surface Area affected (% BSA affected) from Baseline to after two weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to After Two Weeks of Treatment</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Percent decrease from baseline in Body Surface Area treated (% BSA treated) from Baseline to after two weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to End of Treatment</measure>
    <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
    <description>Percent decrease in body surface area affected (%BSA affected) from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to End of Treatment</measure>
    <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
    <description>Percent decrease from baseline in body surface area treated (%BSA treated) from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to Two Weeks Post Treatment</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Percent decrease in body surface area affected (%BSA affected) from Baseline two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to Two Weeks Post Treatment</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Percent decrease in body surface area treated (%BSA treated) from Baseline to two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Weeks Post Treatment</measure>
    <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
    <description>Number of Participants with Tolerability assessments (Pruritus, Telangiectasias, Stinging/Burning, Skin atrophy, Folliculitis) resulting in adverse events from Baseline to two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>clobetasol propionate spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clobetasol propionate spray 0.05%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clobetasol propionate ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clobetasol propionate ointment 0.05%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clobetasol propionate spray</intervention_name>
    <description>Apply twice daily</description>
    <arm_group_label>clobetasol propionate spray</arm_group_label>
    <other_name>ClobexÂ® Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clobetasol propionate ointment</intervention_name>
    <description>Apply twice daily</description>
    <arm_group_label>clobetasol propionate ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of moderate to severe plaque psoriasis, defined as 3% - 20%
             of the body surface area. For the purposes of study treatment, most areas will be
             treated with the exception of face, scalp, groin, axillae and other intertriginous
             areas

          -  Overall disease severity is at least 3 (moderate)

        Exclusion Criteria:

          -  Subjects who have surface area involvement too large that would require more than 50
             grams per week of clobetasol propionate spray or more than 50 grams per week of
             clobetasol propionate ointment

          -  Subjects whose psoriasis involves only the scalp, face or groin

          -  Subjects with non-plaque psoriasis or other related diseases not classified as plaque
             psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Bay Dermatology Medical Group, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute - Dermatology Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <results_first_submitted>April 30, 2009</results_first_submitted>
  <results_first_submitted_qc>July 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2009</results_first_posted>
  <last_update_submitted>April 28, 2014</last_update_submitted>
  <last_update_submitted_qc>April 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject was enrolled on August 22, 2007 and the last subject enrolled was February 20, 2008. Investigative sites were located at academic institutions and private physician offices.</recruitment_details>
      <pre_assignment_details>The specified wash-out period up to baseline was 14 days (topical steroid containing medication and/or UVB treatment, Dovonex, anthralin and/or tar); and 4 weeks (systemic corticosteroids, biologics and/or PUVA treatment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clobetasol Propionate Spray</title>
          <description>clobetasol propionate spray 0.05%</description>
        </group>
        <group group_id="P2">
          <title>Clobetasol Propionate Ointment</title>
          <description>clobetasol propionate ointment 0.05%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clobetasol Propionate Spray</title>
          <description>clobetasol propionate spray 0.05%</description>
        </group>
        <group group_id="B2">
          <title>Clobetasol Propionate Ointment</title>
          <description>clobetasol propionate ointment 0.05%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="14.0"/>
                    <measurement group_id="B2" value="50.2" spread="13.5"/>
                    <measurement group_id="B3" value="50.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale</title>
        <description>Success Rate on Overall Disease Severity (ODS) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe with Clear/Almost Clear being best and Severe/Very Severe being worst) from Baseline to End of Treatment (wk 4 - clobetasol propionate spray; wk 2 - clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
        <population>Intent-to-treat (ITT), Last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale</title>
          <description>Success Rate on Overall Disease Severity (ODS) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe with Clear/Almost Clear being best and Severe/Very Severe being worst) from Baseline to End of Treatment (wk 4 - clobetasol propionate spray; wk 2 - clobetasol propionate ointment)</description>
          <population>Intent-to-treat (ITT), Last observation carried forward (LOCF)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to After Two Weeks of Treatment Based on the Overall Disease Severity (ODS) Scale</title>
        <description>Success Rate on Overall Disease Severity (ODS) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being best and Severe/Very Severe being worst from Baseline to after 2 weeks of treatment</description>
        <time_frame>Baseline and Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to After Two Weeks of Treatment Based on the Overall Disease Severity (ODS) Scale</title>
          <description>Success Rate on Overall Disease Severity (ODS) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being best and Severe/Very Severe being worst from Baseline to after 2 weeks of treatment</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to 2 Weeks Post Treatment Based on the Overall Disease Severity (ODS) Scale</title>
        <description>Success Rate on Overall Disease Severity scale (Clear/Almost Clear, Moderate, Severe/Very Severe) with Clear/Almost Clear being best and Severe/Very Severe being worst at 2 weeks post treatment (week 6 - clobetasol propionate spray and week 4 - clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to 2 Weeks Post Treatment Based on the Overall Disease Severity (ODS) Scale</title>
          <description>Success Rate on Overall Disease Severity scale (Clear/Almost Clear, Moderate, Severe/Very Severe) with Clear/Almost Clear being best and Severe/Very Severe being worst at 2 weeks post treatment (week 6 - clobetasol propionate spray and week 4 - clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to After Two Weeks of Treatment</title>
        <description>Success Rate of decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to After Two Weeks of Treatment</title>
          <description>Success Rate of decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to After Two Weeks of Treatment</title>
        <description>Success Rate of decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to After Two Weeks of Treatment</title>
          <description>Success Rate of decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to After Two Weeks of Treatment</title>
        <description>Success Rate of decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to After Two Weeks of Treatment</title>
          <description>Success Rate of decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost clear being success and all others being failure from Baseline to after 2 weeks of treatment</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to End of Treatment</title>
        <description>Success Rate on decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to End of Treatment</title>
          <description>Success Rate on decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to End of Treatment</title>
        <description>Success Rate on decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to End of Treatment</title>
          <description>Success Rate on decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to End of Treatment</title>
        <description>Success Rate on decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to End of Treatment</title>
          <description>Success Rate on decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to Two Weeks Post Treatment</title>
        <description>Success Rate on decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to Two Weeks Post Treatment</title>
          <description>Success Rate on decrease in Signs of Psoriasis (erythema) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to Two Weeks Post Treatment</title>
        <description>Success Rate on decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to Two Weeks Post Treatment</title>
          <description>Success Rate on decrease in Signs of Psoriasis (scaling) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline to 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to Two Weeks Post Treatment</title>
        <description>Success Rate on decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline and 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to Two Weeks Post Treatment</title>
          <description>Success Rate on decrease in Signs of Psoriasis (plaque elevation) scale (Clear/Almost Clear, Mild, Moderate, Severe/Very Severe) with Clear/Almost Clear being success and all others being failure from Baseline and 2 weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to After Two Weeks of Treatment</title>
        <description>Percent decrease in Body Surface Area affected (% BSA affected) from Baseline to after two weeks of treatment</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to After Two Weeks of Treatment</title>
          <description>Percent decrease in Body Surface Area affected (% BSA affected) from Baseline to after two weeks of treatment</description>
          <population>ITT, LOCF</population>
          <units>% BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="28"/>
                    <measurement group_id="O2" value="35.9" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to After Two Weeks of Treatment</title>
        <description>Percent decrease from baseline in Body Surface Area treated (% BSA treated) from Baseline to after two weeks of treatment</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to After Two Weeks of Treatment</title>
          <description>Percent decrease from baseline in Body Surface Area treated (% BSA treated) from Baseline to after two weeks of treatment</description>
          <population>ITT, LOCF</population>
          <units>% BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="29.6"/>
                    <measurement group_id="O2" value="38.4" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to End of Treatment</title>
        <description>Percent decrease in body surface area affected (%BSA affected) from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to End of Treatment</title>
          <description>Percent decrease in body surface area affected (%BSA affected) from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>% BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="36.5"/>
                    <measurement group_id="O2" value="35.9" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to End of Treatment</title>
        <description>Percent decrease from baseline in body surface area treated (%BSA treated) from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 2 and Baseline and Week 4</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to End of Treatment</title>
          <description>Percent decrease from baseline in body surface area treated (%BSA treated) from Baseline to end of treatment (week 4 for clobetasol propionate spray and week 2 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>% BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="37.5"/>
                    <measurement group_id="O2" value="38.4" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to Two Weeks Post Treatment</title>
        <description>Percent decrease in body surface area affected (%BSA affected) from Baseline two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to Two Weeks Post Treatment</title>
          <description>Percent decrease in body surface area affected (%BSA affected) from Baseline two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>% BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="36.3"/>
                    <measurement group_id="O2" value="37.6" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to Two Weeks Post Treatment</title>
        <description>Percent decrease in body surface area treated (%BSA treated) from Baseline to two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to Two Weeks Post Treatment</title>
          <description>Percent decrease in body surface area treated (%BSA treated) from Baseline to two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
          <population>ITT, LOCF</population>
          <units>% BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="38.0"/>
                    <measurement group_id="O2" value="38.3" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Weeks Post Treatment</title>
        <description>Number of Participants with Tolerability assessments (Pruritus, Telangiectasias, Stinging/Burning, Skin atrophy, Folliculitis) resulting in adverse events from Baseline to two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
        <time_frame>Baseline and Week 4 and Baseline and Week 6</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Clobetasol Propionate Spray</title>
            <description>clobetasol propionate spray 0.05%</description>
          </group>
          <group group_id="O2">
            <title>Clobetasol Propionate Ointment</title>
            <description>clobetasol propionate ointment 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Weeks Post Treatment</title>
          <description>Number of Participants with Tolerability assessments (Pruritus, Telangiectasias, Stinging/Burning, Skin atrophy, Folliculitis) resulting in adverse events from Baseline to two weeks post treatment (week 6 for clobetasol propionate spray and week 4 for clobetasol propionate ointment)</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clobetasol Propionate Spray</title>
          <description>clobetasol propionate spray 0.05%</description>
        </group>
        <group group_id="E2">
          <title>Clobetasol Propionate Ointment</title>
          <description>clobetasol propionate ointment 0.05%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator has the right to publish or present the data results from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald W. Gottschalk, MD / Medical Director</name_or_title>
      <organization>Galderma Laboratories, L.P.</organization>
      <phone>817-961-5358</phone>
      <email>ron.gottschalk@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

